Related Experiment Video
Updated: Jul 20, 2026

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
Published on: November 29, 2024
mTOR pathway as a target in tissue hypertrophy
Chung-Han Lee1, Ken Inoki, Kun-Liang Guan
1Life Science Institute, University of Michigan, Ann Arbor, MI 48109, USA. chunghl@umich.edu
Abstract:
Recent work has shown that the mTOR (mammalian target of rapamycin) pathway is an integral cell growth regulator. The mTOR pathway involves two functional complexes, TORC1 and TORC2, which have been defined by both their association with raptor or rictor, respectively, and their sensitivity to short-term rapamycin inhibition. Loss of tumor suppressors TSC1 or TSC2 leads to aberrant activation of TORC1, which has been implicated in the control of cell size. As a result, both physiologic and pathologic tissue hypertrophy are associated with TORC1 activation. Some clinical examples include skeletal and cardiac muscle hypertrophy, vascular restenosis, and compensatory nephrotic hypertrophy. Clarification of the mTOR pathway may lead to increased understanding of both the etiology and consequences of aberrant cell size regulation. This review covers some of the biochemical regulation of the mTOR pathway that may be important to the regulation of cell size, and it will present several potential clinical applications where the control of cell size may be biologically significant.
Insights
The mammalian target of rapamycin (mTOR) pathway regulates cell growth. Aberrant mTORC1 activation, often due to tumor suppressor loss, drives tissue hypertrophy, offering clinical insights.
Area of Science:
- Biochemistry
- Cell Biology
- Physiology
Background:
- The mammalian target of rapamycin (mTOR) pathway is a critical regulator of cell growth.
- mTOR functions via two complexes, mTORC1 and mTORC2, distinguished by protein partners and rapamycin sensitivity.
- Dysregulation of tumor suppressors TSC1/TSC2 leads to mTORC1 hyperactivation, impacting cell size control.
Purpose of the Study:
- To review the biochemical regulation of the mTOR pathway concerning cell size.
- To explore the clinical significance of mTOR in cell size regulation and hypertrophy.
Main Methods:
- Literature review of biochemical regulation of mTOR.
- Analysis of clinical examples of mTOR-associated hypertrophy.
Main Results:
- TORC1 activation is linked to both physiological and pathological tissue hypertrophy.
- Clinical conditions such as muscle hypertrophy, vascular restenosis, and kidney hypertrophy involve TORC1 activation.
Conclusions:
- Understanding mTOR pathway regulation is key to comprehending aberrant cell size.
- Targeting mTOR may offer therapeutic strategies for conditions characterized by abnormal cell growth.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Cellular Adaptation II: Hypertrophy
TGF - β Signaling Pathway
Regulation of Angiogenesis and Blood Supply